BOC Sciences offers a comprehensive portfolio of Ionizable Lipid Nanoparticle (iLNP) products to meet diverse research and application requirements. Below is a list of our readily available products. If you need iLNPs with specific properties or specifications, please reach out for tailored synthesis based on your project needs.
| Category Type | Product Category | Price |
| By Application Area | mRNA Vaccine iLNPs | Inquiry |
| siRNA Therapy iLNPs | Inquiry | |
| Gene Editing iLNPs | Inquiry | |
| miRNA Modulation iLNPs | Inquiry | |
| ASO Delivery iLNPs | Inquiry | |
| By Administration Route | Intravenous iLNPs | Inquiry |
| Intramuscular iLNPs | Inquiry | |
| Subcutaneous iLNPs | Inquiry | |
| Inhaled iLNPs | Inquiry | |
| Transdermal iLNPs | Inquiry | |
| Intratumoral iLNPs | Inquiry | |
| Oral iLNPs | Inquiry | |
| Intranasal iLNPs | Inquiry | |
| Ocular iLNPs | Inquiry | |
| By Targeting Profile | Liver-Targeted iLNPs | Inquiry |
| Extrahepatic Targeted iLNPs | Inquiry | |
| Cell-Type Specific iLNPs | Inquiry |
Product Specifications
Shipping and Logistics
iLNPs are an advanced nanoscale delivery system primarily composed of four key components: ionizable lipids, cholesterol, helper lipids (e.g., phospholipids), and PEGylated lipids.
At the core are the ionizable lipids, which can change their charge state depending on the pH environment. In acidic conditions (pH ≈ 4.0), the ionizable lipids become protonated, carrying a positive charge. This allows them to efficiently bind negatively charged nucleic acids (such as mRNA, siRNA, or plasmid DNA), forming stable nanoparticles that protect the nucleic acids from enzymatic degradation. In physiological conditions (pH ≈ 7.4), they are mostly neutral or near-neutral, providing excellent in vivo stability and reducing nonspecific interactions with serum proteins.
The delivery process of iLNPs typically involves the following key steps:
iLNP represent an advanced drug delivery platform, playing a pivotal role in the delivery of nucleic acid therapeutics. The core of this system lies in its sophisticated chemical design, which enables reversible charge-state transitions under specific pH conditions, thereby facilitating efficient nucleic acid encapsulation and promoting intracellular delivery.
iLNP formulations typically consist of four essential lipid components, each serving distinct roles to ensure nanoparticle formation, stability, encapsulation efficiency, and biological functionality.
Ionizable Lipid
This is the core functional component of iLNP. Its molecular structure contains an amine headgroup capable of protonation under specific pH conditions. In an acidic environment (e.g., during preparation or within acidic intracellular compartments like endosomes), this group carries a positive charge, enabling efficient binding and encapsulation of negatively charged nucleic acids via electrostatic interactions. At neutral physiological pH, its charge approaches neutrality, which helps minimize nonspecific interactions and prolongs circulation time.
Helper Phospholipid
Serving as the primary structural lipid, the helper phospholipid provides the basic phospholipid bilayer framework for the nanoparticle. These phospholipids typically possess a high phase transition temperature, ensuring the structural integrity and stability of the nanoparticle under storage and use conditions.
Cholesterol
Cholesterol molecules are embedded within the lipid bilayer. By modulating the arrangement and interactions between lipid molecules, cholesterol effectively regulates membrane fluidity, rigidity, and mechanical strength. Its presence is crucial for maintaining the structural stability of the nanoparticle.
PEGylated Lipid
This component forms a hydrophilic, hydrated protective layer on the nanoparticle surface through its polyethyleneglycol (PEG) chains. This steric hindrance effect significantly reduces nonspecific adsorption of plasma proteins, minimizes immune recognition, and thereby extends the in vivo circulation half-life of the nanoparticle.
Fig.1 Schematic diagram of an ionizable lipid nanoparticle (BOC Sciences Original).
The superior performance of iLNP stems from the precise formulation ratios and synergistic interactions among its components.
During the initial preparation phase, the protonated ionizable lipid forms a complex core with the nucleic acid via electrostatic interactions. Helper phospholipids and cholesterol subsequently self-assemble around this core to form a structurally complete lipid bilayer nanoparticle. This cooperative self-assembly process is fundamental to achieving high encapsulation efficiency.
During systemic circulation, the hydrated surface layer formed by PEGylated lipids provides steric shielding, reducing nonspecific interactions between the nanoparticles and blood components, thereby extending their circulation half-life. The near-neutral surface charge further minimizes the potential for nonspecific binding.
Upon cellular uptake, the nanoparticles are endocytosed and trafficked into acidic endosomal compartments. In this environment, the ionizable lipid re-protonates, acquiring a positive charge. This not only promotes nucleic acid release but also facilitates interaction with the negatively charged endosomal membrane, disrupting its stability and promoting the release of nucleic acids into the cytosol—a process known as endosomal escape.
The manufacturing process of iLNP directly determines its physicochemical properties, encapsulation efficiency, and biological activity, making it a critical factor for achieving its intended function.
Current mainstream manufacturing methods are based on the principle of lipid molecular self-assembly during phase transition, achieving controlled nanoparticle formation by regulating mixing conditions.
This technology utilizes precisely engineered microchannels to rapidly collide and mix the organic phase (containing lipids) with the aqueous phase (containing nucleic acids) at a predetermined flow rate ratio. By precisely controlling parameters such as total flow rate, flow rate ratio between phases, and the structure of the mixing chamber, uniformity and reproducibility of the mixing process can be achieved. This method is capable of producing nanoparticles with a very narrow size distribution and is suitable for stages ranging from laboratory research to scaled-up production.
This method involves rapidly injecting an ethanol solution containing dissolved lipids into a stirred aqueous buffer containing nucleic acids. The rapid diffusion and dilution of ethanol in the aqueous phase causes a sharp decrease in lipid solubility, inducing lipid molecules to self-assemble into nanoparticles while simultaneously encapsulating the nucleic acids. This method is relatively simple to operate and is commonly used for laboratory-scale preparation and process exploration.
The particle size of iLNP directly influences its in vivo distribution, cellular uptake, and clearance. The ideal particle size typically ranges between 50 and 150 nanometers. Size control is primarily achieved by adjusting manufacturing parameters, including mixing rate, total lipid concentration, and the ratio of aqueous to organic phases. Generally, faster mixing speeds and higher dilution favor the formation of smaller, more uniform nanoparticles.
Surface properties primarily refer to surface charge, often characterized by Zeta potential. During the preparation stage, selecting an appropriately acidic pH environment ensures the protonation of the ionizable lipid, which is a prerequisite for efficient nucleic acid encapsulation. After preparation, the system is typically exchanged into a physiological neutral pH buffer via methods such as dialysis or tangential flow filtration (TFF). At this point, the ionizable lipid deprotonates, rendering the nanoparticle surface charge near-neutral or slightly negative. This helps maintain colloidal stability and reduces nonspecific interactions.
iLNPs can efficiently encapsulate mRNA, siRNA, and miRNA, protecting them in vivo and enabling controlled intracellular release, enhancing gene expression or silencing efficiency.
Their safety and delivery efficiency make iLNPs ideal carriers for mRNA vaccines, improving antigen stability and immunogenicity to elicit rapid and controlled immune responses.
Surface modification or functionalization allows iLNPs to selectively deliver therapeutics to specific tissues or cells, increasing local drug concentration while minimizing systemic toxicity.
iLNPs can co-deliver small molecules and nucleic acids, supporting combination therapy strategies. Their ionizable nature enables tunable release profiles, optimizing therapeutic outcomes.
iLNPs can stably encapsulate mRNA, siRNA, and other nucleic acids, ensuring high intracellular delivery and enhanced transfection efficiency.
Their tunable charge allows iLNPs to remain neutral in the bloodstream, minimizing cellular and tissue irritation and improving safety.
Controlled Release
pH-sensitive properties enable the release of payloads in acidic intracellular environments, achieving targeted and controlled delivery.
iLNPs can be functionalized with ligands or antibodies to achieve tissue- or cell-specific delivery, increasing therapeutic efficiency.
They can co-deliver nucleic acids and small-molecule drugs, supporting combination therapy strategies and optimizing treatment outcomes.
Techniques like microfluidics enable uniform, large-scale production of iLNPs, facilitating commercial application.
BOC Sciences leverages advanced technologies such as microfluidics to produce iLNPs with high encapsulation efficiency (often >90%) and uniform particle size / low polydispersity, ensuring consistent payload protection and delivery performance.
The company offers tailored iLNP formulations, from lipid composition, particle size, to surface modifications, adapting to different payload types (mRNA, siRNA, small molecules) and application goals (gene therapy, vaccines, targeted delivery).
BOC Sciences supports the full development pipeline: from initial formulation design and small-scale lab preparation through pilot-scale to large-scale production, facilitating a smooth transition from early research to commercial-grade supply.
Their workflow includes thorough characterization, particle size distribution, zeta potential, encapsulation efficiency, stability testing, plus optional in-depth evaluation (in vitro / in vivo), delivering detailed QC reports and ensuring reliable, reproducible iLNP products.
Ionizable lipid nanoparticles enhance delivery performance by leveraging pH-responsive charge modulation. This enables stable payload encapsulation, protection during circulation, and efficient intracellular release, supporting improved bioavailability and high-value targeted delivery.
The platform is highly adaptable and can be engineered for mRNA, siRNA, and DNA. Optimized lipid compositions ensure strong encapsulation efficiency, controlled delivery behavior, and minimized degradation of sensitive payloads.
Through precise control of lipid ratios, pH conditions, and advanced mixing technologies such as microfluidics or high-pressure homogenization, manufacturers achieve uniform particle attributes, consistent encapsulation performance, and strong batch reproducibility to meet development and scale-up needs.
Key evaluation metrics include particle size and distribution, surface charge behavior, encapsulation efficiency, release characteristics, long-term storage stability, and alignment with payload requirements.
Yes. Targeting ligands, PEGylation, and other surface engineering strategies can be incorporated to enhance targeting precision, extend circulation time, and reduce non-specific interactions, enabling flexible customization for diverse application scenarios.
References
